Date: 2011-09-12
Type of information:
Compound: ColoAd1 programme
Company: Ark Therapeutics Group (UK) PsiOxus Therapeutics (UK)
Therapeutic area: Cancer Oncology
Type agreement: Manufacturing
Production
Action mechanism:
Disease: colorectal cancer
Details: Ark Therapeutics Group has signed a manufacturing partnership agreement with PsiOxus Therapeutics Ltd under which Ark will provide full manufacturing and related services to support the development of PsiOxus's ColoAd1 programme for the treatment of colorectal cancer. Ark will work with PsiOxus in providing oncolytic adenoviral material for IV administration in toxicological and Phase I/II clinical studies, utilising Ark's suspension based single use system (ATOSUS).
Financial terms: Financial details of the agreement were not disclosed.
Latest news: * On January 4, 2012, Ark Therapeutics Group and PsiOxus Therapeutics have announced that this partnership has successfully achieved its first milestone, by the timely manufacture of PsiOxus's ColoAd1 oncoloytic adenoviral product. As a result, PsiOxus has initiated final pre-clinical toxicology studies of this product, as scheduled, prior to the planned commencement of a Phase I study in 2012. The material was manufactured at Ark's facility in Kuopio, Finland, using Ark's proprietary suspension based single use process (ATOSUS), which was able to achieve the required product quality and demonstrate capability to exceed target process yields. ColoAd1 is under development by PsiOxus for the treatment of colorectal cancer.
